Psyence Biomedical
About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Employees: 10
0
Funds holding %
of 7,351 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
663% more capital invested
Capital invested by funds: $201K [Q3] → $1.53M (+$1.33M) [Q4]
76.16% more ownership
Funds ownership: 12.06% [Q3] → 88.22% (+76.16%) [Q4]
8% less funds holding
Funds holding: 12 [Q3] → 11 (-1) [Q4]
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for PBM.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.
Neutral
GlobeNewsWire
2 months ago
Psyence Biomed Announces Closing of $2.0 Million Private Placement
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A common warrants expire five years from the date of issuance and the short-term series B common warrants expire two years from the date of issuance.
Neutral
GlobeNewsWire
2 months ago
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Neutral
GlobeNewsWire
2 months ago
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to implement patient recruitment and retention strategies NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psilocybin, in conjunction with psychotherapy, as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care.
Neutral
Newsfile Corp
2 months ago
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP-certified, naturally-derived psilocybin and MDMA, has entered into binding agreements with Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed").
Neutral
GlobeNewsWire
2 months ago
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Biomed obtains exclusive worldwide supply rights to Optimi's GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative Care Psyence Biomed obtains exclusive worldwide supply rights to Optimi's GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative Care
Neutral
GlobeNewsWire
2 months ago
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.
Neutral
GlobeNewsWire
3 months ago
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened balance sheet, with substantially reduced debt, heading into 2025 Psyence Biomed believes it is on track to regain compliance with all applicable Nasdaq continued listing requirements by year-end Phase IIb clinical trial progressing as planned; patient screening has commenced NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today issued the following update to shareholders: Dear shareholders: I wanted to take this opportunity to recap the significant progress that we have made since our last update, as we continue to progress our active Phase IIb clinical trial of nature-derived psilocybin in Palliative Care patients diagnosed with Adjustment Disorder, while also advancing plans for a clinical trial in our second development indication, Alcohol Use Disorder.
Neutral
GlobeNewsWire
3 months ago
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed's shareholders approved a consolidation of the Company's common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company's board of directors (the “Board”). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.
Neutral
GlobeNewsWire
3 months ago
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the “Meeting”).
Charts implemented using Lightweight Charts™